Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-09-28 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
简式权益变动报告
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告" which translates to a "Simplified Equity Change Report." It details the changes in shareholding of an information disclosure obligor (汪璐) in 福安药业（集团）股份有限公司, including the number of shares held before and after the change, the reasons for the change, and future shareholding plans. The document references Chinese securities laws and disclosure standards specifically related to equity changes. It does not contain financial statements, earnings data, or management discussion of financial results. Instead, it focuses on the notification of changes in significant share ownership levels, including the reduction of shareholding below 5%. This matches the definition of a Major Shareholding Notification (MRQ). The document length is over 5,000 characters and contains detailed information about the shareholding change, not just an announcement of a report publication or a certification. Therefore, the correct classification is MRQ with high confidence.
2016-09-28 Chinese
发行股份及支付现金购买资产并募集配套资金之非公开发行股票募集配套资金发行情况报告书
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "发行股份及支付现金购买资产 并募集配套资金之非公开发行股票 募集配套资金发行情况报告书" which translates to "Report on the Non-public Issuance of Shares and Payment of Cash to Purchase Assets and the Issuance of Supporting Funds." It includes extensive information about the issuance process, regulatory approvals, share subscription details, shareholder changes before and after issuance, and the impact on the company. The document references regulatory approvals from the China Securities Regulatory Commission (CSRC), detailed financial and shareholding data, and legal and financial advisor statements. The content is focused on a capital raising event through a non-public share issuance combined with asset acquisition and fundraising. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters), contains substantive financial and procedural details, and is not merely an announcement or a brief summary. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). It is not an Annual Report, Earnings Release, or other categories. Hence, the correct classification is CAP with high confidence.
2016-09-28 Chinese
关于公司及子公司收到药品注册批件、审批意见通知件及临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company (福安药业) regarding the receipt of drug registration approvals, clinical trial permits, and regulatory opinions from the National Medical Products Administration of China. It details specific drug approvals and rejections, clinical trial permissions, and the company's statement on the impact of these regulatory decisions on its business. The document is an announcement of regulatory approvals and related information rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. It is also not a report publication announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-09-28 Chinese
关于以募集资金置换预先已投入募集资金投资项目的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 福安药业（集团）股份有限公司 regarding the replacement of self-raised funds previously invested in projects with raised funds from a non-public share issuance. It details the fundraising approval by the China Securities Regulatory Commission, the amount raised, the use of funds, and approvals by the board and supervisory committee. It includes references to verification reports and independent opinions but does not contain full financial statements or comprehensive financial performance data. The document is relatively short (2687 characters) and serves as a formal disclosure of a capital/financing update related to the company's fundraising and use of proceeds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2016-09-13 Chinese
独立董事关于第三届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent directors' opinion on a specific board meeting matter related to the use of raised funds and self-raised funds replacement. It references regulatory guidelines for independent directors and company internal rules. The document is short (810 characters) and contains no financial statements or detailed financial data. It is a formal opinion or statement related to board meeting decisions rather than a full report or announcement of voting results. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a certification letter or a regulatory filing in the usual sense but a formal independent director opinion on a board matter. Given the nature and content, the best fitting category is Board/Management Information (MANG), which covers announcements related to board or senior management matters, including independent directors' opinions on board decisions.
2016-09-13 Chinese
关于公司以自筹资金预先投入募集资金投资项目专项说明的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a verification report issued by a certified public accounting firm regarding a special explanation on the use of self-raised funds to pre-invest in projects funded by raised capital. It references regulatory guidelines related to the management and use of raised funds by listed companies, and includes detailed financial figures and audit opinions. The document is titled as a "鉴证报告" (verification or attestation report) and contains the auditor's opinion on the accuracy and compliance of the special explanation. It is not a full annual or interim financial report, nor is it a simple announcement. It is a standalone audit-related report focusing on a specific regulatory compliance matter related to fundraising and capital use. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (5607 characters) supports it being a full report rather than a brief announcement or certification only. FY 2016
2016-09-13 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.